Specific N-terminal mutations in the human androgen receptor induce cytotoxicity

@article{Funderburk2009SpecificNM,
  title={Specific N-terminal mutations in the human androgen receptor induce cytotoxicity},
  author={Sarah F. Funderburk and L. Shatkina and S. Mink and Q. Weis and S. Weg-Remers and A. Cato},
  journal={Neurobiology of Aging},
  year={2009},
  volume={30},
  pages={1851-1864}
}
Polyglutamine (polyQ) stretch amplification in different proteins causes neurodegenerative disease. These proteins form intracellular aggregates thought to be cytotoxic but differ in pathology and tissue specificity. Here, we demonstrate that specific sequences outside the polyQ stretch of the human androgen receptor contribute to polyQ pathology. An exchange of two N-terminal serine phosphorylation residues to alanine in the wild type androgen receptor (ARQ22dm) resulted in cytoplasmic… Expand
Effects of N-terminal mutations of human androgen receptor on polyglutamine toxicity
Nine neurodegenerative diseases are caused by polyglutamine (polyQ) tract amplification in different proteins. The cytotoxicity of each of these proteins is associated with a misfolding of the mutantExpand
Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures.
TLDR
Melatonin, which is known to ameliorate the pathological phenotype in the fly model, caused polyQ-extended AR to form annular oligomers, and comparative investigation of these reproducibly distinct toxic and non-toxic oligomers could advance the understanding of the molecular basis of the polyQ pathologies. Expand
Mechanisms Mediating Spinal and Bulbar Muscular Atrophy: Investigations into Polyglutamine-Expanded Androgen Receptor Function and Dysfunction
TLDR
Investigation into polyQ AR function have shown that multiple complex mechanisms lead to the initiation and progression of SBMA, a late-onset neuromuscular disorder caused by expansion of the polymorphic polyglutamine tract in the androgen receptor. Expand
Neurotoxic protein oligomerisation associated with polyglutamine diseases
TLDR
Initial evidence suggests that conformational changes induced by polyQ expansions and their surrounding sequence lead to the formation of particular oligomeric intermediates that may differentially affect neurotoxicity. Expand
Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer
TLDR
Functional characterization of selected LBD mutant alleles showed diverse effects on AR activity, with about half of the mutations reducing transactivation in vitro, suggesting Mutant ARs may use multiple mechanisms to evade cancer treatment. Expand
Functional significance of androgen receptor mutations in prostate and breast cancer
TLDR
Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer and identifies mutations that occurred multiple times within the population were differentially located dependent on treatment. Expand
Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity.
TLDR
How post-translational modifications of the polyglutamine proteins contribute to modulate neurotoxicity is reviewed. Expand
Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases
TLDR
Recent publications are discussed that define other important therapeutic targets for polyglutamine‐mediated neurodegeneration related to the context of the expanded polyglUTamine tract in the disease protein. Expand
Insights from AR Gene Mutations
The accumulation of somatic mutations on the background of natural germline variation is one of the fundamental mechanisms underpinning both disease and the development and progression of perhaps allExpand
Intrinsic Brain Signaling Pathways: Targets of Neuron Degeneration
TLDR
Results support a disease model where disease initiation and subsequent neuronal dysfunction are distinct from progression to cell death, and form the basis of a small molecule inhibitor screen that could provide an effective treatment for SCA1. Expand
...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Cytoplasmic Localization and the Choice of Ligand Determine Aggregate Formation by Androgen Receptor with Amplified Polyglutamine Stretch
TLDR
It is demonstrated that in addition to the cytoplasmic localization, a distinct contribution of the ligand binding domain of the receptor is necessary for the aggregation, which may provide the basis for in vivo determination of the role of these structures in SBMA. Expand
Androgen-Dependent Neurodegeneration by Polyglutamine-Expanded Human Androgen Receptor in Drosophila
TLDR
It is suggested that the full binding of androgen to the polyQ-expanded hAR mutants leads to structural alteration with nuclear translocation that eventually results in the onset of SBMA in male patients. Expand
Androgen Receptor Acetylation Site Mutations Cause Trafficking Defects, Misfolding, and Aggregation Similar to Expanded Glutamine Tracts*
TLDR
A novel role for the acetylation site as a regulator of androgen receptor subcellular distribution and folding is identified and indicates that ligand-dependent aggregation is dependent upon intact Hsp90 function. Expand
Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity.
TLDR
It is shown that expanded polyglutamine AR is phosphorylated by Akt, and IGF-1 rescue of AR toxicity is diminished by alanine substitutions at the Akt consensus sites, highlighting potential targets for therapeutic intervention in SBMA. Expand
Histone deacetylase inhibitors reduce polyglutamine toxicity
TLDR
It is suggested that nuclear accumulation of polyglutamine can lead to altered protein acetylation in neurons and indicate a novel therapeutic strategy for polyglUTamine disease. Expand
Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length.
TLDR
It is concluded that the AR NTD contributes to AR transactivation activity via functional interactions with p160 coactivators and that increasing polyQ length negatively affects p160-mediated coactivation of the AR. Expand
Flanking sequences profoundly alter polyglutamine toxicity in yeast.
TLDR
Using a yeast model, this work finds that sequences flanking the polyQ region of human huntingtin exon I can convert a benign protein to a toxic species and vice versa, and observes that flanking sequences can direct polyQ misfolding to at least two morphologically distinct types of polyQ aggregates. Expand
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.
TLDR
It is postulate that this residual AR activity may be sufficient for development of male primary and secondary sex characteristics, but may fall below a threshold level of activity necessary for normal maintenance of motor neuron function. Expand
Reduced transcriptional regulatory competence of the androgen receptor in X–linked spinal and bulbar muscular atrophy
TLDR
It is found that a polyglutamine (Gln) expanded AR transactivates an androgen–responsive reporter gene subnormally and causes the AR to lose a function necessary for full androgen sensitivity and to gain a function that is selectively motor neuronotoxic. Expand
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
TLDR
It is shown that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). Expand
...
1
2
3
4
5
...